The effects of angiotensin-converting enzyme inhibitors in heart recipients: a single center experience-Reference-Cited by-同舟云学术

The effects of angiotensin-converting enzyme inhibitors in heart recipients: a single center experience

Published:2019-01-31 Issue:4 Volume:20 Page:14-21
ISSN:2412-6160
Container-title:Russian Journal of Transplantology and Artificial Organs
language:
Short-container-title:RJTAO

Author:

Shevchenko А. О.¹,Faradzhov R. A.²,Izotov D. A.³,Koloskova N. N.³,Nikitina Е. A.³,Gichkun O. E.⁴,Orlov V. I.³,Tunyaeva I. Yu.³,Mironkov B. L.³

Affiliation:

1. V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University); N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of the Russian Federation

2. N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of the Russian Federation

3. V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation

4. V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University)

Abstract

Aim.To study the effect of ACE inhibitors (ACEI) in heart recipients on the prognosis and myocardial remodeling.Materials and methods.Three hundred and eighty-six patients who received orthotopic heart transplantation (HT) were consequently enrolled to the study from February 2009 to November 2016.Results.Thirty days after the HT, ACEIs were assigned to 141 recipients. Arterial hypertension was diagnosed in all cardiac recipients who received ACEI and among 48 patients (19.5%) from non-ACEI group. Patients receiving ACEI had significantly better event-free survival than control group (p = 0.045) during the follow-up for 1361,6 ± 36,9 days. Left ventricle (LV) end-diastolic dimension did not change over the time in both groups, whereas LV posterior wall thickness in non-ACEI group significantly increased from 1.35 ± 0.03 cm to 1,23 ± 0.05 cm (p < 0.05).Conclusion.Cardiac recipients who received ACE inhibitors had better survival and less transplant left ventricle progression, that could reflect beneficial effects of renin-aldosterone-angiotensin system inhibition after heart transplantation.

Publisher

V.I. Shimakov Federal Research Center of Transplantology and Artificial Organs

Subject

Transplantation,Immunology and Allergy

Reference16 articles.

1. Foreman KJ, Marquez N, Dolgert A et al. Forecasting life expectancy, years of life lost, and all-cause and causespecific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018; 392: 2052–2090.

2. Mareev VYu, Fomin IV, Ageev FT i dr. Klinicheskie rekomendatsii OSSN – RKO – RNMOT. Serdechnaya nedostatochnost': khronicheskaya (KhSN) i ostraya dekompensirovannaya (ODSN). Diagnostika, profilaktika i lechenie. Kardiologiya. 2018; 58 (S6): 8–164. Mareev VYu, Fomin IV, Ageev FT i dr. Klinicheskie rekomendacii OSSN – RKO – RNMOT. Serdechnaya nedostatochnost’: hronicheskaya (HSN) i ostraya dekompensirovannaya (ODSN). Diagnostika, profilaktika i lechenie. Kardiologiya. 2018; 58 (S6): 8–164.

3. Fomin IV. Khronicheskaya serdechnaya nedostatochnost' v Rossiiskoi Federatsii: chto segodnya my znaem i chto dolzhny delat'. Rossiiskii kardiologicheskii zhurnal. 2016; 8: 7–13. Fomin IV. Chronic heart failure in Russian Federation: what do we know and what to do. Russian journal of cardiology. 2016; 8: 7–13. doi: 10.15829/1560-4071-2016-8-7-13.

4. Donorstvo i transplantatsiya organov v Rossiiskoi Federatsii v 2017 godu (X soobshchenie registra Rossiiskogo transplantologicheskogo obshchestva). Transplantologiya: itogi i perspektivy. Tom IX. 2018 god / Pod red. S. V. Got'e. M. –Tver': Triada, 2018: 392, 26–63. Organ donation and transplantation in Russian Federation in 2018 (X report of National Registry). Transplantology: results and prospects. Vol. IX. 2016 / Ed. by S. V. Gautier. M. –Tver: Triad, 2018: 392, 26–63.

5. Goland S, Czer LSC, Kass RM et al. Use of Cardiac Allografts With Mild and Moderate Left Ventricular Hypertrophy Can Be Safely Used in Heart Transplantation to Expand the Donor Pool. Journal of the American College of Cardiology. 2008; 51: 1214–1220. doi: 10.1016/j.jacc.2007.11.052.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting the transplantation of donor heart with left ventricular myocardial hypertrophy;Transplantologiya. The Russian Journal of Transplantation;2020-03-18